Abstract:Background: Chinese guideline recommends using combination therapy of antidiabetic-drug plus metformin for type 2 diabetes (T2DM) patients failed to control glucose on metformin. Treatment effect varies between antidiabetic drugs, but there is no direct evidence on comparing the effect of each alternative drug plus metformin. This study aims to estimate and compare the efficacy and safety of seven classes of antidiabetic-drug added onto metformin for Chinese T2DM patients failed on metformin. Methods: Systematic review was performed by searching databases including CNKI, WanFang, CQVIP, PubMed, EMBASE, Web-of-Science, ScienceDirect, Cochrane-Library, to identify randomized controlled trials(1990-2016) comparing the treatment effect of 'antidiabetic-drug + metformin vs metformin' or 'metformin vs placebo/lifestyle-intervention' in Chinese T2DM patients. Based on Chinese guideline, three-line eight-class of antidiabetic-drugs were included: 1st-line-drug(metformin), 2nd-line-drug/oral-drug(α-glycosidase inhibitor, sulfonylurea, glinide, DPP-4 inhibitor, thiazolidinedione), 3rd-line-drug/injectable-drug(insulin, GLP-1 receptor agonist). Using metformin as common comparator, meta-analyses and indirect-treatment-comparisons were used to estimate the effect of 'antidiabetic-drug + metformin vs placebo/lifestyle-intervention'. Findings: 325 studies were finally included. Overall, compared with placebo/lifestyle-intervention, 'oral-drug + metformin' and 'injectable-drug + metformin' reduced HbA1c level by 1·89% and 2·28%, BMI level by 2·55kg/m2 and 3·10kg/m2, TC level by 1·03mmol/l and 1·50mmol/l, SBP level by 5·59mmHg and 8·51mmHg, while increased HDL-C level by 0·31mmol/l and 0·18mmol/l, respectively. In 'oral-drug + metformin', the top two treatments for reducing HbA1c level were 'glinide + metformin' (WMD:-2·03,95%CI[-2·70,-1·36]) and 'sulfonylurea + metformin' (WMD:-2·00,95%CI[-2·64,-1·36]); for reducing BMI level were 'glinide + metformin' (WMD:-4·25,95%CI[-5·70,-2·80]) and 'DPP-4 inhibitor + metformin' (WMD:-2·81,95%CI[-4·22,-1·40]); for reducing TC level were 'α-glycosidase inhibitor + metformin'(WMD:-1·41,95%CI[-2·15,-0·68]) and 'DPP-4 inhibitor + metformin' (WMD:-1·22,95%CI[-1·71,-0·73]); for increasing HDL-C level were 'α-glycosidase inhibitor + metformin'(WMD:0·51,95%CI[0·27,0·75]) and 'thiazolidinedione + metformin' (WMD:0·35,95%CI[0·10,0·60]). In 'injectable-drug + metformin', 'GLP-1 receptor agonist + metformin' was superior to 'insulin + metformin' in reducing HbA1c level (WMD:-2·42vs-2·04) and BMI level (WMD:-3·27vs-2·05), while inferior to 'insulin + metformin' in reducing TC level (WMD:-1·43vs-1·79). All combination therapies had no significant difference on risks of hypoglycemia or gastrointestinal-reaction vs placebo/lifestyle-intervention. Interpretation: Pharmacological combination therapies had better efficacy than placebo/lifestyle-intervention in Chinese T2DM patients. Funding: No funding was received. Declaration of Interest: There are no relevant conflicts of interest to disclose.

Research on Curative Effect of Liuwei Dihuang Pill Combined with Metformin on Type 2 Diabetes and Serum Apolipoprotein Level

[Effect of Yuquan Pill on Proinflammatory Cytokines in Patients with Type 2 Diabetes Mellitus].

Clinical observation of "DM120 Decoction" for type 2 diabetes mellitus: A report of 30 cases

Study on clinical effect of Yiqi Yangyin and Huoxue Prescription imposed on fatty liver in type 2 diabetes mellitus

Liuwei Dihuang Pills (a...a(3)ae Degrees E >>"A) Enhance the Effect of Western Medicine in Treating Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials

Effects of Liu wei di huang pills on the vascular endothelial function in type 2 diabetes mellitus

Clinical Observation on 46 Cases of Type 2 Diabetes Mellitus Complicated with Fatty Liver Treated by Yiqi Yangyin and Huoxue Herbal Medicines

Effects of DPP-4 Inhibitor Combined with Metformin on Blood Glucose Control,oxidative Stress and Inflammatory Response in Patients with Type 2 Diabetes Mellitus

Efficacy and Safety of Pharmacological Combination Therapies for the Treatment of Type 2 Diabetes in China: A Systematic Review and Meta-Analysis

Clinical observation on the effects of yiqi Huaju herb formula on type 2 diabetes subjects coupled with central obesity

A Double-Blind Randomized Multiple Center Clinical Trial on Observing the Effect of Fixed-Dose Glipizide/metformin on Type 2 Diabetes

PP93 Efficacy of Pharmacological Treatments for Type 2 Diabetes in China

Lipid Profiling Reveals Different Therapeutic Effects of Metformin and Glipizide in Patients with Type 2 Diabetes and Coronary Artery Disease

Study of Relation Between Insulin Resistance and Fatty Liver in Type 2 Diabetes and Clinical Effect of Yiqi Yangyin and Huoxue Prescription

Comparative clinical trial of the traditional Chinese medicine hypoglycemic composing prescription and metformin in the treatment of type 2 diabetes mellitus

Clinical Observation on Qihuangjiangtang Capsule in the Treatment of Type 2 Diabetes Mellitus

Effect of metformin on adipose tissue distribution and hepatic lipid content in patients with type 2 diabetes

Analysis of the effect of sitagliptin on the clinical effcacy and renal function of patients with type 2 diab-etes mellitus

The efficacy of Da Chaihu decoction combined with metformin tablets for type 2 diabetes mellitus: A systematic review and meta-analysis

Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome

A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus